Tyra Biosciences(TYRA) - 2025 Q4 - Annual Results

Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - Dabogratinib 3x3 Strategy TYRA is focused on ...